138 completed. 138 Phase 2, 19 Phase 1, 19 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 138 | Completed 138 |
| Phase 1 | 19 | Completed 19 |
| Phase 3 | 19 | Completed 19 |
Follow Attention Deficit and Disruptive Behavior Disorders: new trials by email Literature Review of Attention Deficit and Disruptive Behavior Disorders trials Research Report on Attention Deficit and Disruptive Behavior Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder Cannabigerol, Placebo - Attention-Deficit/Hyperactivity Disorder | Phase 2 | Completed | University of Arkansas, Fayetteville | 67 | 2024-12-14 | 2026-11-04 |
| Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD) NRCT-101-SR, Placebo - ADHD | Phase 2 / Phase 3 | Completed | Neurocentria, Inc. | 223 | 2023-02-25 | 2025-06-03 |
| PDC-1421 Treatment in Adult Patients With ADHD PDC-1421 Capsule, Placebo - Attention-Deficit Hyperactivity Disorder (ADHD) | Phase 2 | Completed | BioLite, Inc. | 99 | 2022-04-07 | 2026-05-06 |
| Methylphenidate in Childhood Apraxia of Speech Methylphenidate Hydrochloride, Placebo - Childhood Apraxia of Speech | Phase 2 | Completed | Murdoch Childrens Research Institute | 18 | 2022-03-14 | 2026-10-13 |
| Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial MM120, Placebo - ADHD, Attention Deficit Disorder | Phase 2 | Completed | Definium Therapeutics US, Inc. | 53 | 2021-12-17 | 2026-02-27 |
| COMT Inhibition Among Individuals With Comorbid AUD/ADHD Tolcapone, Placebo - Alcohol Use Disorder, Attention Deficit Hyperactivity Disorder | Phase 2 | Completed | University of Colorado, Denver | 23 | 2021-08-16 | 2026-05-04 |
| A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults Solriamfetol 75 MG, Solriamfetol 150 MG, Placebo - Attention Deficit Hyperactivity Disorder | Phase 2 / Phase 3 | Completed | Massachusetts General Hospital | 66 | 2021-08-06 | 2024-03-04 |
| Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1 N-Acetyl cysteine, Placebo - Neurofibromatosis 1 | Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 25 | 2021-02-23 | 2026-06-05 |
| Intranasal Inhalations of M2 Macrophage Soluble Factors in Children With Developmental Speech Disorders Bioactive Factors, Produced by M2 Type Macrophages (M2-BFs). - Language Delay, Language; Developmental Disorder, Expressive | Phase 1 / Phase 2 | Completed | Russian Academy of Medical Sciences | 14 | 2020-02-01 | 2022-05-02 |
| CTx-1301 Comparative Bioavailability Study Dexmethylphenidate 5 Mg Oral Capsule, Extended Release, Dexmethylphenidate 6.25 mg Tablet, Dexmethylphenidate 40 Mg Oral Capsule, Extended Release - ADHD | Phase 1 / Phase 2 | Completed | Cingulate Therapeutics | 45 | 2019-12-06 | 2021-04-08 |
| A Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD) PDC-1421 Capsule - Attention-Deficit Hyperactivity Disorder (ADHD) | Phase 2 | Completed | BioLite, Inc. | 6 | 2019-12-01 | 2021-12-01 |
| Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD) Centanafadine - Attention Deficit Hyperactivity Disorder | Phase 2 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 13 | 2019-10-07 | 2023-01-13 |
| Amphetamine Extended Release Tablets and Driving Performance in Subjects With Attention Deficit/Hyperactivity Disorder (ADHD) Amphetamine Extended Release (ER) Tablet 20 mg - ADHD | Phase 2 | Completed | Tris Pharma, Inc. | 41 | 2019-10-01 | 2022-02-18 |
| PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations AEVI-001, Placebo - Attention Deficit Hyperactivity Disorder | Phase 2 | Completed | Aevi Genomic Medicine, LLC, a Cerecor company | 109 | 2018-08-17 | 2021-07-30 |
| Micronutrients for Attention-Deficit Hyperactivity Disorder in Youth (MADDY) Study Broad Spectrum Micronutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants, Placebo - Attention Deficit Hyperactivity Disorder | Phase 1 / Phase 2 | Completed | Oregon Health and Science University | 135 | 2018-04-23 | 2023-02-08 |
| The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder OPC-64005, Atomoxetine, Placebo - Adult Attention Deficit Hyperactivity Disorder | Phase 2 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 239 | 2017-11-09 | 2021-10-29 |
| PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations AEVI-001, Placebo - Attention Deficit Hyperactivity Disorder | Phase 2 | Completed | Aevi Genomic Medicine, LLC, a Cerecor company | 69 | 2017-08-28 | 2021-07-07 |
| Prevention of Comorbid Depression and Obesity in Attention-deficit/ Hyperactivity Disorder Bright light therapy, Physical exercise - Attention-Deficit / Hyperactivity Disorder, Depression | Phase 2 | Completed | Goethe University | 207 | 2017-03-13 | 2020-10-19 |
| Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders Oxytocin, Placebo - Mood Disorder, Disruptive Behavior Disorders | Phase 2 | Completed | University of Nebraska | 58 | 2017-01-27 | 2023-10-05 |
| Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD) mazindol - Attention Deficit Disorder With Hyperactivity | Phase 2 | Completed | NLS Pharmaceutics | 84 | 2016-08-01 | 2017-04-06 |
Showing 20 of 138. Sign in to see all of them.
Attention Deficit Disorder with Hyperactivity (129) · Conduct Disorder (7) · Substance-Related Disorders (6) · Depression (5) · Impulsive Behavior (5) · Spasm (5) · Cocaine-Related Disorders (4) · Alcoholism (3) · Amphetamine-Related Disorders (2) · Anxiety Disorders (2) · Autism Spectrum Disorder (2) · Autistic Disorder (2) · Brain Injuries, Traumatic (2) · Chorea (2)
Mental Disorders (137) · Neurodevelopmental Disorders (137) · Behavior (15) · Nervous System Diseases (15) · Pathological Conditions, Signs and Symptoms (15) · Signs and Symptoms (14) · Chemically-Induced Disorders (13) · Neurologic Manifestations (12) · Substance-Related Disorders (7) · Behavioral Symptoms (6) · Central Nervous System Diseases (5) · Neuromuscular Manifestations (5) · Brain Diseases (4) · Child Development Disorders, Pervasive (4)
Methylphenidate (20) · Atomoxetine Hydrochloride (16) · Lisdexamfetamine Dimesylate (6) · pozanicline (6) · Amphetamine (4) · Dextroamphetamine (4) · SLI381 (4) · Tablets (4) · Sugars (3) · 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine (2) · Capsules (2) · Dexmethylphenidate Hydrochloride (2) · Exercise (2) · Guanfacine (2) · SEP 225289 (2)
New York State Psychiatric Institute (6) · AbbVie (prior sponsor, Abbott) (5) · Eli Lilly and Company (5) · Otsuka Pharmaceutical Development & Commercialization, Inc. (5) · Shire (5) · Alcobra Ltd. (4) · Massachusetts General Hospital (4) · Supernus Pharmaceuticals, Inc. (4) · Aevi Genomic Medicine, LLC, a Cerecor company (3) · Children's Hospital Medical Center, Cincinnati (3) · Ironshore Pharmaceuticals and Development, Inc (3) · New River Pharmaceuticals (3) · University of Pittsburgh (3) · Abbott (2) · AstraZeneca (2)
United States (91) · Canada (10) · Israel (8) · Japan (5) · Germany (3) · Netherlands (3) · Taiwan (3) · United Kingdom (3) · Australia (1) · China (1) · Finland (1) · India (1) · Malaysia (1) · Norway (1) · Poland (1)
Craig Surman, MD (4) · Frances R Levin, M.D. (3) · Ann Childress, M.D. (2) · Christian Fleischhaker, MD (2) · Earle Bain, MD (2) · Frances R Levin, MD (2) · Heather Boon, PhD (2) · Iris Manor, MD (2) · Klaus Hennighausen, MD (2) · Laura Gault, MD, PhD, MD (2) · Leigh J Beglinger, Ph.D. (2)
PMID 20732631, PMID 21156272, PMID 10385840, PMID 11514638, PMID 16041867, PMID 16102908, PMID 16481664, PMID 16890481, PMID 17284136, PMID 17631866, PMID 18469236, PMID 18544723, PMID 18632997, PMID 19849639, PMID 19877974, PMID 20048226, PMID 20215923, PMID 20406576, PMID 20445835, PMID 20445836, PMID 20445837, PMID 20680193, PMID 20869813, PMID 20973706, PMID 21265936, PMID 21356232, PMID 21476931, PMID 21597989, PMID 21748252, PMID 21807480, PMID 22024004, PMID 22170209, PMID 22313788, PMID 22372512, PMID 22519922, PMID 22795204, PMID 23106988, PMID 23115630, PMID 23290324, PMID 23344135, PMID 23660970, PMID 23738530, PMID 23856296, PMID 23933905, PMID 24043939, PMID 24375941, PMID 24493927, PMID 24523588, PMID 24664093, PMID 24840045
K23NS055733 (1), K24AA000301 (1), P50DA009236 (1), R01AA026859 (1), R01DA011444 (1), R01DA019233 (1), R01DA022217 (1), R01DA023652 (1), R01MH063272 (1), R01MH064707 (1), R01MH067949 (1), R01MH072263 (1), R01MH082864 (1), R01MH082865 (1), R01NS039087 (1)